Search This Blog

Monday, December 2, 2019

Aquestive +8% premarket on completing NDA submission for libervant buccal film

Aquestive Therapeutics (NASDAQ:AQST) completes the rolling submission of a NDA to the FDA for its therapeutic candidate Libervant (diazepam) Buccal Film for the management of seizure clusters.
The company plans to share the results from the single dose crossover study at the upcoming American Epilepsy Society 2019 Annual Meeting.
Shares are up 8% premarket.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)